PLUS THERAPEUTICS, INC. (PSTV): Nasdaq/NYSE listing notice — Plus Therapeutics receives Nasdaq delisting notice for equity deficiency

PLUS THERAPEUTICS, INC.

Stockholders' equity was ($1,348,000) as of Dec 31, 2023, below Nasdaq's $2.5M minimum.
Company has 45 days (until Apr 22, 2024) to submit a plan to regain compliance.
If accepted, Nasdaq may grant up to 180 days (until Sep 4, 2024) to cure the deficiency.
Company plans to pursue capital raising to satisfy the equity or alternative standards.
Failure to regain compliance could result in delisting of PSTV common stock.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PLUS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

March 8, 2024, Plus Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it no longer complies with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Equity Standard”) or the alternative requirements of having a market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-068002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.